Ⓐ
PeptiBrief
Evidence Library
phase_2_clinical_study · 2015

ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes

Brines M|et al. · Molecular Medicine
moderatePMID · 25387363Verified
View source
Plain-English summary

Reported improvements in selected neuropathy and metabolic measures that require confirmation.

Population
People with type 2 diabetes and neuropathy
Intervention
ARA-290
Outcomes measured
Neuropathy symptoms|metabolic measures|nerve markers
Key findings
Promising exploratory signals.
Limitations
Small exploratory study|Multiple outcomes|No phase 3 confirmation
Risk of bias
Moderate.
Citation
Brines M|et al. (2015). ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Molecular Medicine
Linked peptides in the PeptiBrief database
ImportantPeptiBrief is an educational information platform. It does not diagnose, prescribe, sell peptides, recommend dosing, encourage self-experimentation or replace qualified medical care. Published scientific evidence is kept separate from community observations and uncertainty.